GlaxoSmithKline: HIV Infections trials

The registry lists 265 HIV Infections studies with GlaxoSmithKline as lead sponsor. 15 are open to participants now and 99 have results posted.

Phase 1 84Phase 2 53Phase 3 68Phase 4 18No phase 47(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV DrugsCompletedNCT00002442Phase 2
• A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsCompletedNCT00002440Phase 2
• The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZTCompletedNCT00002436Phase 3
• A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include AmprenavirCompletedNCT00002423Phase 2
• A Study of Amprenavir in Patients With Protease Inhibitor-Related ComplicationsCompletedNCT00002417Not applicable
• The Effect of Teaching HIV-Infected Patients About HIV and TreatmentCompletedNCT00002409Phase 3
• A Study of Amprenavir in HIV-Infected PatientsCompletedNCT00002405Not applicable
• The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected PatientsCompletedNCT00002404Not applicable
• Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)CompletedNCT00002395Phase 2
• The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 DrugsCompletedNCT00002391Phase 3
• A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected PatientsCompletedNCT00002390Phase 2
• The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV DrugsCompletedNCT00002389Phase 3
• A Study of 1592U89 in HIV-Infected PatientsCompletedNCT00002388Phase 1
• The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected PatientsCompletedNCT00002373Phase 1
• A Study of 141W94 in Combination With Other Anti-HIV DrugsCompletedNCT00002372Phase 1
• A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV DrugsCompletedNCT00002364Phase 2
• A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMXCompletedNCT00002340Phase 3
• The Safety and Effectiveness of 935U83 in HIV-Infected PatientsCompletedNCT00002338Phase 1
• The Safety and Effectiveness of 524W91CompletedNCT00002335Phase 1
• A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the PastCompletedNCT00002320Phase 3
• A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune SystemsCompletedNCT00002315Phase 3
• The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV InfectionCompletedNCT00002290Not applicable
• The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous SystemCompletedNCT00002288Not applicable
• A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the VirusCompletedNCT00002287Not applicable
• A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive PatientsCompletedNCT00002286Not applicable
• A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDSCompletedNCT00002285Not applicable
• A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow TransplantCompletedNCT00002284Not applicable
• A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected PatientsCompletedNCT00002245Phase 3
• A Study of a Combination of Four Drugs in Patients With Recent HIV InfectionCompletedNCT00002233Phase 2
• A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV DrugsCompletedNCT00002217Not applicable
• A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV TreatmentCompletedNCT00002216Not applicable
• The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease InhibitorsCompletedNCT00002213Phase 2
• An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment RegimenCompletedNCT00002205Not applicable
• A Study of Two Anti-HIV Drug CombinationsCompletedNCT00002203Not applicable
• A Comparison of 141W94 and Indinavir in HIV-Infected PatientsCompletedNCT00002202Phase 3
• A Study of 1592U89 in HIV-Infected AdultsCompletedNCT00002200Not applicable
• A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.CompletedNCT00002199Phase 3
• A Study of 1592U89 and Ethanol When Given Together to HIV-Infected PatientsCompletedNCT00002198Phase 1
• A Study of 1592U89 in HIV-Infected ChildrenCompletedNCT00002197Not applicable
• A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected PatientsCompletedNCT00002195Phase 3
• Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease InhibitorsCompletedNCT00002193Phase 3
• A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal MicrosporidiosisCompletedNCT00002191Phase 3
• A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV InfectionCompletedNCT00002183Phase 1
• A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia ComplexCompletedNCT00002163Phase 3
• A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89CompletedNCT00002141Phase 1
• 3TC (Lamivudine; GR109714X) Open-Label ProgramCompletedNCT00002108Not applicable
• A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3CompletedNCT00002106Phase 2
• A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV InfectionCompletedNCT00002086Phase 2
• A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected PatientsCompletedNCT00002084Not applicable
• Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)CompletedNCT00002063Not applicable
• The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)CompletedNCT00002048Not applicable
• Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal FailureCompletedNCT00002047Not applicable
• A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARCCompletedNCT00002046Not applicable
• A Prospective Double-Blind Study of Retrovir in Early HIV InfectionCompletedNCT00002045Not applicable
• A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular DiseasesCompletedNCT00002044Not applicable
• Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)CompletedNCT00002026Not applicable
• An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2CompletedNCT00002023Not applicable
• Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARCCompletedNCT00002020Not applicable
• A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)CompletedNCT00002014Phase 1
• The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus DiseaseCompletedNCT00002001Not applicable
• A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected PatientsCompletedNCT00002000Not applicable
• A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / SulfamethoxazoleCompletedNCT00001996Phase 2
• A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-SulfadiazineCompletedNCT00001994Not applicable
• A Treatment IND for 566C80 Therapy of Pneumocystis Carinii PneumoniaCompletedNCT00001991Not applicable
• An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral PentamidineCompletedNCT00001990Not applicable